These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 10414920

  • 1. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia.
    Clark RE, Grzybowski J, Broughton CM, Pender NT, Spiller DG, Brammer CG, Giles RV, Tidd DM.
    Bone Marrow Transplant; 1999 Jun; 23(12):1303-8. PubMed ID: 10414920
    [Abstract] [Full Text] [Related]

  • 2. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J, Wu B, Liu Q, Feng R, Liu X, Meng F, Zhou S.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [Abstract] [Full Text] [Related]

  • 3. Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients.
    Broughton CM, Spiller DG, Pender N, Komorovskaya M, Grzybowski J, Giles RV, Tidd DM, Clark RE.
    Leukemia; 1997 Sep; 11(9):1435-41. PubMed ID: 9305594
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 5. Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia.
    Broughton CM, Sherrington P, Pender NT, Clark RE.
    Genes Chromosomes Cancer; 1997 Apr; 18(4):292-8. PubMed ID: 9087569
    [Abstract] [Full Text] [Related]

  • 6. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 7. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.
    Spiller DG, Giles RV, Grzybowski J, Tidd DM, Clark RE.
    Blood; 1998 Jun 15; 91(12):4738-46. PubMed ID: 9616172
    [Abstract] [Full Text] [Related]

  • 8. Mobilization of hematopoietic progenitors in patients with chronic myeloid leukemia.
    Thijsen SF, Schuurhuis GJ, van Oostveen JW, Theijsmeijer AP, Niewint AW, Ossenkoppele GJ.
    Bone Marrow Transplant; 1997 Nov 15; 20(10):835-42. PubMed ID: 9404923
    [Abstract] [Full Text] [Related]

  • 9. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH, Runkel K, Steckel N, Opalka B, Trenschel R, Seeber S, Schaefer UW, Beelen DW.
    Bone Marrow Transplant; 2001 Apr 15; 27(8):809-15. PubMed ID: 11477437
    [Abstract] [Full Text] [Related]

  • 10. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
    Maki G, Tam YK, Berkahn L, Klingemann HG.
    Bone Marrow Transplant; 2003 Jun 15; 31(12):1119-25. PubMed ID: 12796791
    [Abstract] [Full Text] [Related]

  • 11. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ, Li JL, Zhu HH, Ruan GR, Li LD, Zhang Y, Xu LP, Liu DH, Liu YR, Huang XJ, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug 15; 27(8):511-4. PubMed ID: 17172121
    [Abstract] [Full Text] [Related]

  • 12. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J, Serrano J, Jiménez A, Castillejo JA, Reina ML, González MG, Rodríguez MC, García I, Sánchez J, Maldonado J, Torres A.
    Haematologica; 2000 Feb 15; 85(2):173-80. PubMed ID: 10681725
    [Abstract] [Full Text] [Related]

  • 13. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
    de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F.
    Blood; 1998 May 01; 91(9):3156-62. PubMed ID: 9558370
    [Abstract] [Full Text] [Related]

  • 14. Collection and analysis of peripheral blood mononuclear cells during haemopoietic recovery following PBSCT for CML: autografting as an in vivo purging manoeuvre?
    Spencer A, Granter N, Fagan K, Zaunders G, Deveridge S.
    Bone Marrow Transplant; 1998 Jan 01; 21(1):101-3. PubMed ID: 9486504
    [Abstract] [Full Text] [Related]

  • 15. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
    Clark RE.
    Leuk Lymphoma; 1995 Oct 01; 19(3-4):189-95. PubMed ID: 8535209
    [Abstract] [Full Text] [Related]

  • 16. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
    Prejzner W.
    Med Sci Monit; 2002 May 01; 8(5):BR193-7. PubMed ID: 12011769
    [Abstract] [Full Text] [Related]

  • 17. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells.
    Rapoport AP, Levine BL, Badros A, Meisenberg B, Ruehle K, Nandi A, Rollins S, Natt S, Ratterree B, Westphal S, Mann D, June CH.
    Bone Marrow Transplant; 2004 Jan 01; 33(1):53-60. PubMed ID: 14578928
    [Abstract] [Full Text] [Related]

  • 18. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation.
    de Fabritis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F.
    Leukemia; 1995 Apr 01; 9(4):662-4. PubMed ID: 7536864
    [Abstract] [Full Text] [Related]

  • 19. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.
    Warashina M, Kuwabara T, Nakamatsu Y, Taira K.
    Chem Biol; 1999 Apr 01; 6(4):237-50. PubMed ID: 10099134
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S, Onida F, Beran M, Champlin RE, de Lima M.
    Bone Marrow Transplant; 2004 May 01; 33(10):1005-9. PubMed ID: 15048141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.